Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.10 -1.9%	$2.11	$1.43 ▼ $3.98	$214.88M	1.65	146,427 shs	69,794 shs
CHUC Charlie's	$0.20 +5.3%	$0.12	$0.03 ▼ $0.24	$49.86M	0.95	267,118 shs	454,843 shs
CRGX CARGO Therapeutics	$4.47	$4.44	$3.00 ▼ $25.45	$216.17M	0.3	1.73 million shs	N/A
VTYX Ventyx Biosciences	$2.65 +3.5%	$2.62	$0.78 ▼ $3.39	$182.55M	0.97	819,882 shs	301,962 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	+4.39%	-2.73%	+2.88%	+26.25%	-36.69%
CHUC Charlie's	-9.52%	+11.76%	+106.52%	+127.54%	+108.79%
CRGX CARGO Therapeutics	-1.11%	+0.22%	-1.11%	+9.02%	-73.94%
VTYX Ventyx Biosciences	-2.66%	-10.18%	-13.22%	+40.66%	+30.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	1.715 of 5 stars	3.5	1.0	0.0	0.8	0.6
CHUC Charlie's	0.6928 of 5 stars	0.0	5.0	0.6	1.7	0.0
CRGX CARGO Therapeutics	2.0577 of 5 stars	2.9	0.0	1.8	1.7	1.3
VTYX Ventyx Biosciences	2.4705 of 5 stars	3.3	3.0	1.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	471.43% Upside
CHUC Charlie's	0.00	N/A	N/A	N/A
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	244.52% Upside
VTYX Ventyx Biosciences	2.50	Moderate Buy	$7.50	183.02% Upside

Current Analyst Ratings Breakdown

Latest CHUC, CRGX, VTYX, and ACIU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$31.02M	6.80	N/A	N/A	$0.90 per share	2.33
CHUC Charlie's	$8.49M	6.18	N/A	N/A	($0.01) per share	-20.00
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$2.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$57.83M	-$0.58	N/A	N/A	N/A	-174.94%	-49.35%	-23.16%	11/4/2025 (Estimated)
CHUC Charlie's	-$4.16M	-$0.01	N/A	∞	N/A	-55.89%	N/A	-104.63%	N/A
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	N/A
VTYX Ventyx Biosciences	-$135.12M	-$1.68	N/A	N/A	N/A	N/A	-48.89%	-44.87%	11/6/2025 (Estimated)

Latest CHUC, CRGX, VTYX, and ACIU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	CHUC Charlie's	N/A	$0.02	N/A	$0.02	N/A	N/A
8/7/2025	Q2 2025	VTYX Ventyx Biosciences	-$0.45	-$0.38	+$0.07	-$0.38	N/A	N/A
8/5/2025	Q2 2025	ACIU AC Immune	-$0.20	-$0.25	-$0.05	-$0.25	$1.98 million	$1.65 million
5/29/2025	Q4 2024	CHUC Charlie's	N/A	-$0.01	N/A	-$0.01	N/A	$1.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
CHUC Charlie's	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.33	1.33
CHUC Charlie's	N/A	0.51	0.06
CRGX CARGO Therapeutics	N/A	12.37	12.37
VTYX Ventyx Biosciences	N/A	19.12	19.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
CHUC Charlie's	7.80%
CRGX CARGO Therapeutics	93.16%
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
CHUC Charlie's	20.90%
CRGX CARGO Therapeutics	2.92%
VTYX Ventyx Biosciences	14.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	95.79 million	Optionable
CHUC Charlie's	40	262.43 million	207.59 million	Not Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A
VTYX Ventyx Biosciences	30	71.31 million	60.98 million	Optionable

CHUC, CRGX, VTYX, and ACIU Headlines

Recent News About These Companies

Ventyx Biosciences Reports Decreased Losses in 2025

August 15, 2025 | msn.com

3 Best Stocks to Buy Now, 8/11/2025, According to Top Analysts

August 11, 2025 | msn.com

Ventyx Biosciences (NASDAQ:VTYX) Rating Increased to Hold at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Ventyx Biosciences (NASDAQ:VTYX) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

August 10, 2025 | marketbeat.com

Wall Street Zen Upgrades Ventyx Biosciences (NASDAQ:VTYX) to "Hold"

August 10, 2025 | marketbeat.com

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

August 9, 2025 | finance.yahoo.com

Ventyx (VTYX) Q2 Net Loss Drops 16%

August 9, 2025 | theglobeandmail.com

Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Expands By 69,900.0%

August 2, 2025 | marketbeat.com

Monaco Asset Management SAM Has $1.31 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

July 30, 2025 | marketbeat.com

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

July 22, 2025 | uk.finance.yahoo.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - Nasdaq

July 11, 2025 | nasdaq.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 10, 2025 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)

June 24, 2025 | theglobeandmail.com

VTYX - Ventyx Biosciences Inc News - Morningstar

June 24, 2025 | morningstar.comM

VTYX - Ventyx Biosciences Inc Financials - Morningstar

June 24, 2025 | morningstar.comM

Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m

June 17, 2025 | finance.yahoo.com

Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives

June 17, 2025 | marketwatch.com

Ventyx says Parkinson’s disease drug hit main goal in small mid-stage trial

June 17, 2025 | msn.com

Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results

June 17, 2025 | msn.com

Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data

June 17, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHUC, CRGX, VTYX, and ACIU Company Descriptions

AC Immune NASDAQ:ACIU

$2.10 -0.04 (-1.87%)

Closing price 04:00 PM Eastern

Extended Trading

$2.09 -0.01 (-0.48%)

As of 07:11 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Charlie's OTCMKTS:CHUC

$0.20 +0.01 (+5.26%)

As of 03:58 PM Eastern

Charlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.

CARGO Therapeutics NASDAQ:CRGX

$4.47 0.00 (0.00%)

As of 08/19/2025

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Ventyx Biosciences NASDAQ:VTYX

$2.65 +0.09 (+3.52%)

Closing price 04:00 PM Eastern

Extended Trading

$2.64 0.00 (-0.19%)

As of 07:35 PM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time